New Delhi: Meril Life Sciences has launched MyClip, India’s first Transcatheter Edge-to-Edge Repair (TEER) system for treating severe mitral regurgitation (MR), the company announced.
The device was unveiled during the Structural Heart Innovation event held from June 13 to 15 at Meril Academy in Vapi, Gujarat. The conference brought together more than 150 Indian interventional cardiologists and international experts, including Prof. Ottavio Alfieri, Prof. Francesco Maisano, and Prof. Agricola.
MyClip offers a minimally invasive option for patients with MR who are considered high-risk for surgery due to conditions such as diabetes, hypertension, obesity, advanced age, or heart failure. The TEER procedure takes about one hour and typically allows patients to return home within 3 to 5 days.
Mitral regurgitation, if untreated, can lead to high mortality. Studies indicate that one-year death rates may reach 57% in severe cases without intervention.
Meril said the device is designed to precisely close leaking mitral valve flaps, preventing blood from flowing backward into the lungs. The company is also investing in physician training and building cardiac imaging expertise to expand access to the therapy across India.
“In India, around 1.5 million people are known to suffer from severe mitral regurgitation,” said Sanjeev Bhatt, Senior Vice President, Corporate Strategy at Meril. “The launch of MyClip is a significant step toward addressing this critical need.”
The company cited findings from the COAPT study published in the New England Journal of Medicine, which showed that TEER therapy led to reduced hospitalizations and lower mortality compared to standard medical therapy.
Currently, around 150 TEER procedures are performed annually in India, primarily among patients aged 30 to 60.
Meril is also running a nationwide awareness campaign, #TreatmentZarooriHai, featuring MS Dhoni, to educate the public about early treatment for mitral valve disease.
With the launch of MyClip, Meril becomes the first Indian company to offer both transcatheter valve replacement (TAVI) and repair (TEER) technologies, positioning India as a growing hub for structural heart innovations.
